A Study of NTX-1472 in Social Anxiety Disorder
Eligible age
18–65 yrs
Accepts
All genders
Locations
7 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD). The main questions this trial aims to answer are: * Is NTX-1472 safe and well tolerated in adults with SAD? * How effectively does NTX-1472 treat adults with SAD? Researchers will compare the effects of NTX-1472 with matching placebo (a look-alike capsule that contains no drug). Participants will: * Take NTX-1472 or matching placebo every day for 8 weeks * Visit the clinic 6 times over the course of 14 weeks for checkups and tests
Sponsor: Newleos Therapeutics, Inc.
Where it's recruiting
Encino · Los Angeles · Oceanside · San Jose
Jacksonville · Tampa
Boston
Las Vegas
Brooklyn
Memphis
Austin
Source: ClinicalTrials.gov · NCT07323784 · last updated 2026-07-09